tbuckley/cabot-search huggingface dataset:
Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
Authors: Toni K. Choueiri, Sumanta Kumar Pal, David F. McDermott, David A. Ramies, Stephanie Morrissey, Yihua Lee, Dale Miles, Jaymes Holland, Janice P. Dutcher
Journal: Journal of Clinical Oncology (2012)

4504 Background: Cabozantinib (cabo) is an oral, potent inhibitor of MET and VEGFR2 that is currently undergoing evaluation in several oncology indications. Renal cell carcinoma (RCC) was chosen as an indication in this drug-drug interaction (DDI) study based on involvement of the MET and VEGFR signaling pathways in this disease. The primary objective of this study is to determine the effect of cabo on single dose PK of the CYP2C8 substrate rosiglitazone (rosi). Anti-tumor activity was also evaluated. Methods: Eligible pts were required to have RCC with clear cell components with metastases, Karnofsky performance status of ≥70 and measurable disease by RECIST. Pts needed to have experienced PD following standard therapies. Cabo was given daily at a dose of 140 mg free base (equivalent to 175 mg salt form) starting at Day 2. Rosi (4 mg) was given Day 1 and Day 22 to complete PK assessment for DDI. Cabo was continued until PD. On Day 57 and every 8 weeks thereafter subjects underwent tumor assessments by mRECIST. Results: Enrollment is complete at 25 RCC pts; 17/25 (64%) RCC pts had received ≥ 2 prior agents; 13/25 (52%) with at least 1 VEGF pathway inhibitor and 1 mTOR inhibitor. The majority of pts were in an intermediate (21/25) or poor (3/25) prognostic category (1/25 in favorable category) per Heng et al (JCO, 2009, v27, p5794). ORR by mRECIST: 7/25 (28%). Disease control rate (PR + SD): 72% at 16 weeks; 19/21 (90%) pts with ≥1 post-baseline scan experienced tumor regression (range: 4 - 63% reduction in measurements). 10/25 (36%) pts remain on cabo. Median PFS is 14.7 months (95% CI: 7.3, upper limit not reached) with a median follow-up of 7.7 months. AEs ≥ Grade 3 severity: hypophosphatemia (36%), hyponatremia (20%), and fatigue (16%). PK data suggest that clinically relevant doses of cabo do not alter the C max or AUC 0-24h of rosi, consistent with no inhibition of CYP2C8. Conclusions: Cabo demonstrates encouraging anti-tumor activity in heavily pretreated RCC pts with a toxicity profile similar to that of other VEGFR TKIs. PK data suggest no DDI between cabo and rosi (CYP2C8 substrate).
Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.
Authors: Youn H. Kim, Sunil Reddy, Ellen J. Kim, Alain H. Rook, Adam Lerner, Mariefrance Demierre, Madeleine Duvic, Sean Whittaker, Tadeusz Robak, Jurgen C. Becker, William McCulloch, Archibald G. Prentice
Journal: Blood (2007)
Cas-L/Hef1 Is Required for Marginal Zone B Cell Maintenance and Lymphocyte Trafficking.
Authors: Sachiko Seo, Takashi Asai, Toshiki Saito, Takahiro Suzuki, Motoshi Ichikawa, Seishi Ogawa, Mineo Kurokawa, Shigeru Chiba, Hisamaru Hirai
Journal: Blood (2005)
Untreated Tetralogy of Fallot With Pulmonary Atresia in a 55-Year-Old Woman
Authors: Michael Puderbach, Joachim Eichhorn, Christian Fink, Hans-Ulrich Kauczor
Journal: Circulation (2004)

A 55-year-old woman with congenital heart disease and increasing dyspnea at low levels of exertion was referred to our department for imaging.Clinical findings were cyanosis of the lips and clubbing of the fingers.The past medical history included several hospitalizations for dyspnea, tachycardia, recurrent pulmonary embolism, and suspected cerebral embolism.Despite several conventional angiographic studies, the exact classification of the congenital heart disease and the vascular abnormalities had not been made because of the complex cardiovascular morphology.The presumptive diag-nosis was truncus arteriosus type IV.Differential diagnosis included tetralogy of Fallot with pulmonary atresia.To reevaluate the morphology and to assess acute pulmonary, cardiac, and thoracic vessel problems, MRI was performed (Figures 1 to 4).It revealed a ventricular septal defect with overriding aorta, pulmonal atresia with collateral blood supply by major aortopulmonary collateral arteries, and collateral arteries originating from the right phrenic arteries and intercostal arteries.These findings are consistent with tetralogy of Fallot with pulmonary atresia.
Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia.
Authors: Mark C. Lanasa, Sallie D. Allgood, Barbara K. Goodman, John F. Whitesides, Jon P. Gockerman, Joseph O. Moore, J. Brice Weinberg, Marc C. Levesque
Journal: Blood (2007)
OP0197-HPR Psychosocial Predictors of DMARD Adherence in The First Three Months of Treatment for Early Arthritis
Authors: A. Pasma, J.M. Hazes, J.J. Busschbach, W.H. van der Laan, C. Appels, Y. de Man, D. Nieboer, R. Timman, A. van 't Spijker
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> To induce disease remission, early arthritis patients should adhere to their disease-modifying antirheumatic drugs (DMARD) in the first months after diagnosis.<sup>1</sup> It remains unknown why some patients do not adhere to their therapy. <h3>Objectives</h3> In this study we aimed to identify which patients are at risk for non-adherence in the first 3 months of treatment. <h3>Methods</h3> Adult DMARD-naïve early arthritis patients who started synthetic DMARDs were recruited for a cohort study. At baseline, patients filled out items on potential adherence predictors. These items were based on a literature review and focus group interviews.<sup>2</sup> Items included amongst others questions on coping with pain and the disease, anxiety and depression, and beliefs and expectations about medication. Adherence was in the first 3 months of treatment continuously measured with electronically monitored pill bottles. Items were reduced and clustered using principal component analysis. Per cluster of items, latent trait models were constructed to extract the most discriminating items. Per DMARD and per day non-adherence was defined as not opening the pill bottle when it should have been. We conducted a multilevel multivariable logistic regression model to find predictors for non-adherence. <h3>Results</h3> 301 patients agreed to participate of which 259 completed follow-up. Adherence was high and declined over time. Principal component analysis led to 7 dimensions, while the subsequent latent trait models analyses led to 15 dimensions. Of these dimensions, “information seeking” and “having positive expectations about the disease” were associated with adherence and the dimension “adjusting to the pain” was associated with non-adherence (see table 1). <h3>Conclusions</h3> Our findings suggest that patients who experience autonomy through information seeking behavior and having positive expectations about the course of the disease are more prone to be adherent than patients who feel less autonomous and become passive because of pain: these patients are at risk for non-adherence. <h3>References</h3> Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014 Mar;73:492–509. Pasma A, Hazes JMW, Luime JJ, Busschbach JJV, van 9t Spijker A. How to study determinants related to medication adherence in newly diagnosed polyarthritis patients for the development of a prediction instrument. Patient Preference and Adherence 2014;8:1437–47. <h3>Disclosure of Interest</h3> None declared
Anti-CD20 Antibody GA101 in Combination with Chemotherapy or Flavopiridol in Mantle Cell Lymphoma.
Authors: Daniel A. Heinrich, Christian Klein, Kristina Decheva, Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Tobias Weiglein, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2009)
A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD
Authors: Divya Tiwari, John Horan, Amelia Langston, Muna Qayed, Jennifer Carr, Heather Renfroe, Couture Cynthia, Hanna J. Khoury, Robertson Jennifer, R. Donald Harvey, Aneesh Mehta, Edmund K. Waller, Leslie S. Kean
Journal: Blood (2012)
Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study
Authors: Esther GM Waal de, Linda Munck de, Gerhard Woolthuis, Annet velden Van Der, Yvonne Tromp, Mels Hoogendoorn, Edo Vellenga, Sjoerd Hovenga
Journal: Blood (2014)
Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells.
Authors: Alan G. Ramsay, Dong-Xia Xing, William K. Decker, Jared K. Burks, William G. Wierda, John G. Gribben, Elizabeth J. Shpall
Journal: Blood (2008)
AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia.
Authors: Masahiro Nakagawa, Munetake Shimabe, Nahoko Nishimoto, Naoko Watanabe-Okochi, Motoshi Ichikawa, Yasuhito Nannya, Yoichi Imai, Mineo Kurokawa
Journal: Blood (2009)
Hepatic Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplantation in Children: Retrospective Analysis in a Single Institution.
Authors: Hoon Kook, Seok Joo Kim, Kyoung Ran Sohn, Hee Jo Baik, Ha Young Noh, Young Kook Cho, Jun Seung Sung, Ho Song Nam, Tai Ju Hwang
Journal: Blood (2004)
A Novel Murine Model for Human Waldenstrom’s Macroglobulinemia.
Authors: Pierfrancesco Tassone, Paola Neri, Jeffery Kutok, Olivier Tournilhac, Daniel Ditzel Santos, Evdoxia Hatjiharissi, Salvatore Venuta, Kenneth C. Anderson, Steven Treon, Nikhil C. Munshi
Journal: Blood (2004)
PTH-126 Virtual Reality and Beyond: Integrating Simulation into The Gastroenterology Training Curriculum
Authors: R Gadhok, S Murray, E Wood
Journal: Gut (2016)

<h3>Introduction</h3> Simulation has been increasingly utilised in medical education since the publication of Safer Medical Practice.<sup>1</sup> Some specialities have led the way in integrating simulation training into curricula to cover technical and higher-level non-technical skills training. To date simulation in gastroenterology has largely restricted itself to the use of virtual reality endoscopy training. Even then, there is insufficient evidence to demonstrate how best to integrate this into the curriculum, so this remains untackled.<sup>2</sup> In 2015 UCLPartners funded a Gastroenterology Simulation Fellow, based at The Homerton Hospital, to consider how best to use simulation to deliver multi-professional training across UCLP Trusts. Among the aims has been optimising trainee preparation for learning endoscopy; improving inter-professional training; addressing a need for higher-level skills training; creating sustainability in delivering training; and engaging trainees in reflective practice that is little utilised as a tool elsewhere in training. <h3>Methods</h3> Over the course of a year we are delivering 15 one-day courses from 4 UCLParters trusts. They include courses in Screen-based Endoscopy Technical Skills, Human-Factors in Virtual Endoscopy and Situational Training in Gastroenterology. The courses are open to both gastroenterology and endoscopy nurses and gastroenterology and surgical registrars, matching different courses to different training grades. We are evaluating the courses by means of written feedback using both Likert Scales and freetext. We will analyse both quantitative and qualitative data to evaluate how well received the courses were; how well they addressed specific demands of the curriculum and revalidation requirements; and whether they successfully addressed elements of the curriculum not met elsewhere. We are also undertaking faculty feedback to ascertain explore the perception of increasing simulation training in gastroenterology and identify any barriers to the ongoing delivery of training. <h3>Results</h3> Early results from the first courses seem to indicate that they were well received with high levels of enjoyment and engagement, and that there may be significant gaps in the training programme which may best be met by simulation. By early June we will have undertaken collation of all data from course feedback, and analysis as above. <h3>Conclusion</h3> The results will inform the integration of simulation into the training program and local curriculum over the coming years and how to create sustainability to achieve this. <h3>References</h3> 1 Donaldson, L. 2008 Annual Report of the Chief Medical Officer On the State of Public Health. London: Department of Health. 2009. 2 Harpham-Lockyer L, <i>et al</i>. Role of virtual reality simulation in endoscopy training. <i>World J Gastrointest Endosc</i>. 2015 Dec 10; <b>7</b>(18):1287–1294. <h3>Disclosure of Interest</h3> None Declared
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway
Authors: Elisa Alghisi, Michele Malagola, Cristina Santoriello, Martin Distel, Christiaan Henkel, Cristina Skert, Carla Filì, Cesare Bergonzi, Simone Perucca, Alessandro Turra, Andrea Di Palma, Valeria Cancelli, Rossella Ribolla, Federica Cattina, Simona Zedda, Simona Bernardi, Domenico Russo, Marina Mione
Journal: Blood (2012)
Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS.
Authors: XiaoWen Tang, Marcos De Lima, Wei Wei, Alexandre Chiattone, Peter F. Thall, Medeiros Jeffrey, Gabriela Rondon, Julianne J Chen, Elizabeth J. Shpall, Roy Jones, Yago Nieto, Amin M Alousi, Richard E. Champlin, Borje S Andersson
Journal: Blood (2010)
Histogenesis and Pathogenesis of Primary Breast Lymphoma.
Authors: Davide Rossi, Eva Berra, Mirella Marino, Daniela Capello, Michaela Cerri, Clara Deambrogi, Silvia Franceschetti, Chiara Vendramin, Annarita Conconi, Maria Concetta Petti, Annunziata Gloghini, Antonino Carbone, Gianluca Gaidano
Journal: Blood (2004)
Intermediate Dose Intravenous Methotrexate (MTX) Dramatically Reduces the Risk of Secondary Central Nervous System (CNS) Lymphoma.
Authors: Ephraim P. Hochberg, Peter Hammerman, Tak Takvorian, Christiana Toomey, James Michaelson, Aliyah Rahemtullah, Jeremy S. Abramson
Journal: Blood (2007)
Concurrent Loss Of Ezh2 and Tet2 Cooperates In The Pathogenesis Of Myelodysplastic Disorders,
Authors: Tomoya Muto, Goro Sashida, Motohiko Oshima, George R Wendt, Makiko Mochizuki-Kashio, Masashi Sanada, Satoru Miyagi, Atsunori Saraya, Chiaki Nakaseko, Koutaro Yokote, Kazuya Shimoda, Haruhiko Koseki, Yutaka Suzuki, Sumio Sugano, Seishi Ogawa, Atsushi Iwama
Journal: Blood (2013)
THU0597 Comparaison of Self Assessment of Disease Activity To Das28 in Rheumatoid Arthritis: Data from The Randomized “Roc” Trial
Authors: C. Sordet, E. Chatelus, P. Ravaud, J. Sibilia, J.-E. Gottenberg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In rheumatoid arthritis (RA), self assessment of disease activity by patients could be useful in clinical practice. Data in literature regarding the relevance of self-assessment remain limited. We therefore addressed this issue in the Rotation Or Change of biologics (ROC) trial. <h3>Objectives</h3> To compare self-assessment of disease activity by patients to assessment of disease activity by physicians in RA. <h3>Methods</h3> The ROC trial randomized patients with an insufficient response to a 1st anti-TNF to receive either a second anti-TNF or a non-TNF targeted biologic. At enrollment in the trial, a very brief oral information on self assessment of disease activity, along with a short written reminder, was provided to patients. Within 2 weeks of enrollment and at 6 months, patients received a phone call by a clinical research technician to collect the self-DAS28 (patient-derived DAS28). The clinical research technician was unaware of the arm of randomization and of the result of the DAS28. The concordance between self-DAS28 and DAS-28-ESR assessed by the physician was analyzed using the Bland and Altmann method. <h3>Results</h3> At enrollment, self-DAS28 was collected in 97 patients treated with a non TNF-targeted biologic and in 94 patients treated with a second anti-TNF. Mean (SD) self-DAS28 was 4.97 (1.46) and mean DAS28-ESR assessed by the physician was 5.06 (1.10). The systematic difference between self DAS-28 and DAS28 (statistically significant if the confidence interval does not include 0) was -0.11 [-0.29; 0.07]. Thus, self-DAS28 at enrollment sligthly but not significantly underestimated DAS28 assessed by the physician. At 6 months, self-DAS28 was collected in 91 patients treated with a non TNF-targeted biologic and in 84 patients treated with a second anti-TNF. Mean (SD) self-DAS28 was 3.82 (1.56) and mean DAS28-ESR assessed by the physician was 3.53 (1.40). The systematic difference between self DAS-28 and DAS28 was 0.29 [0.09; 0.46]. Thus, self-DAS28 sligthly but not significantly overestimated DAS28 at 6 months. <h3>Conclusions</h3> Self-assessment of disease activity by patients, even without a long period of training, provides a correct appreciation of genuine disease activity in RA. Self-assessment of disease activity could be helpful for patients to have a better perception of disease activity between times of referrals to their rheumatologist, and might therefore contribute to optimize disease control in RA. <h3>Disclosure of Interest</h3> None declared
Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS).
Authors: Ingrid Pabinger, Cihan Ay, Daniela Dunkler, Johannes Thaler, Eva-Maria Reitter, Christine Marosi, Christoph Zielinski, Christine Mannhalter
Journal: Blood (2012)
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
Authors: Clémence Granier, Charles Dariane, Pierre Combe, Virginie Verkarre, Saïk Urien, Cécile Badoual, Hélène Roussel, Marion Mandavit, Patrice Ravel, Mathilde Sibony, Lucie Biard, Camélia Radulescu, Emeline Vinatier, Nadine Benhamouda, Michael Peyromaure, Stéphane Oudard, Arnaud Méjean, Marc-Olivier Timsit, Alain Gey, Eric Tartour
Journal: Cancer Research (2016)

Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+ T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8+ T cells coexpressing PD-1 and Tim-3 correlated with an aggressive phenotype and a larger tumor size at diagnosis. Coexpression of PD-1 and Tim-3 above the median conferred a higher risk of relapse and a poorer 36-month overall survival. Notably, other CD8+T-cell subsets did not exert a similar effect on overall survival. Moreover, only the PD-1+Tim-3+ subset of CD8+ T cells exhibited impaired function after stimulation. Our findings establish intratumoral Tim-3+PD1+CD8+ T cells as critical mediators of an aggressive phenotype in RCC. Use of the Vectra tool may be useful to identify similarly critical prognostic and predictive biomarkers in other tumor types and their response to immunotherapy. Cancer Res; 77(5); 1075-82. ©2016 AACR.
Caffeic Acid Phenethyl Ester Induces Apoptosis in Acute Myeloid Leukemia Cells - Possible Role of Chemokine/G-Protein Signaling.
Authors: Priscila S. Scheucher, Guilherme Augusto Silva dos Santos, Hamilton Luiz G Teixeira, Roberto P. Falcao, Eduardo Magalhaes Rego
Journal: Blood (2009)
In Vitro Purging in Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukaemia. A Retrospective Analysis on Behalf of the Chronic Leukaemia Working Party of the EBMT.
Authors: Loic Fouillard, Mauricette Michallet, Anja Van-biezen, D.W. Miligan, Paolo Corradini, Norbert Claude Gorin, Dietger Niederwieser
Journal: Blood (2004)
PTH-054 Home-Testing of Faecal Calprotectin Using the IBDoc™ System: A Comparative Pilot Study
Authors: H Parr, P Pavlidis, IY Liew, LM Choong, L Medcalf, G Chung-Faye, P Dubois, R Sherwood, B Hayee
Journal: Gut (2016)

<h3>Introduction</h3> Faecal calprotectin (FCAL) is a useful test for monitoring of inflammatory bowel disease (IBD) activity. Providing a stool sample in person to the hospital laboratory is an anecdotally unpopular method with poor uptake. A new FCAL kit (IBDoc™, Bühlmann Labs AG, Switzerland) enables self-testing using a proprietary collection tube, camera smartphone and app. The aim of this study was to assess patient's adherence to, and experience of, a testing regimen using IBDoc™, as well as benchmarking the assay to the standard laboratory test. <h3>Methods</h3> After focussed training, participants were asked to test using IBDoc™ once a month for four months and provide a standard stool sample which was posted to the hospital laboratory overnight and refrigerated on receipt, to be tested with standard ELISA (Bühlmann). The following questionnaires were applied before and after testing: GAD-7 (anxiety), PHQ-9 (depression), IBD-control-8, Multi-dimensional Health Locus of control (MHLC) and Cognitive Behavioural Responses to Symptoms (CBSRQ). Patients were also asked to record their experiences and preferences for testing on a proprietary questionnaire. REC reference 15/WA/0168. <h3>Results</h3> 54 consecutive patients (Crohn's: 23, UC: 31, F = 28, mean age 36.0 ± 9.2 yrs) were enrolled. Participants completed a median of 3 tests (0–4) during the study with 19/54 (35%) completing all four set time points and 17/54 (32%) returning no samples, despite active reminders. There was no difference in any of the questionnaire scores between compliant and non-compliant patients. There was moderate correlation of numerical FCAL results between the two testing methods (r = 0.77, 95%CI 0.68–0.84, p &lt; 0.0001). Categorising results into disease activity categories (no inflammation, mild, moderate, severe) produced a similar result (weighted κ =0.57, p &lt; 0.0001). 63% of respondents stated a preference for IBDoc™<sub>, </sub>but stated that (in a routine clinical scenario) they would require timely contact from the hospital team in the event of an abnormal result (24–72 hours). A further 22% preferred the IBDoc™ test, but stated that they would not contact until their next scheduled appointment. <h3>Conclusion</h3> There was reasonable uptake and adherence to a demanding testing regimen (more frequent testing than might be required in routine clinical care) with 85% of respondents preferring the IBDoc™ test over other methods. The home testing kit results show only moderate correlation to laboratory ELISA. While this is a promising and clearly popular technology, therefore, further studies are warranted to correlate results to clinical outcomes. <h3>Disclosure of Interest</h3> None Declared
Evaluation of Alternative, “Low-intensity” Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML).
Authors: Eric J. Feldman, Ellen Ritchie, Usama Gergis, Sebastian Mayer, Joseph M. Scandura, Paul J. Christos, Usama Wissa, Gail J. Roboz
Journal: Blood (2009)
Detection of sjTRECs within Peripheral Blood T Cells Evaluation of Recent Thymic Output Function in Myelodysplastic Syndrome.
Authors: Xin Du, Yang-qiu Li, Jian-yu Weng, Ze-sheng Lu, Rong Guo, Sui-jing Wu, Li-ye Zhong, Miao-rong She, Wei Lin, Zi-lun Huang
Journal: Blood (2005)